Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.

With regard to other patient-reported outcomes, nominally significant differences favouring baricitinib 4 mg over placebo at week 16 in BREEZE-AD1 and BREEZE-AD2 were seen in the proportions of patients achieving clinically relevant (i.e. ≥ 4-point and ≥ 3.4-point improvement from baseline [ 23 ]) skin pain and Patient-Oriented Eczema Measure (POEM) responses and improvements in itch (as assessed by the Itch NRS) and the POEM total score (Table 2 ).

also in 7,732 other papers